Free Trial

DBV Technologies Q1 2024 Earnings Report

DBV Technologies logo
$3.05 -0.04 (-1.29%)
(As of 05:31 PM ET)

DBV Technologies EPS Results

Actual EPS
-$1.40
Consensus EPS
-$2.20
Beat/Miss
Beat by +$0.80
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$1.41 million
Expected Revenue
$3.20 million
Beat/Miss
Missed by -$1.79 million
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

DBV Technologies Earnings Headlines

DBV Technologies Aligns with FDA for Viaskin Peanut Approval
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
DBV jumps 52% to $4.99 after aligning with FDA on approval pathway
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

View DBV Technologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings